ProCE Banner Activity

Especialistas respondem às suas perguntas sobre inibidores de CDK4/6 no câncer de mama HR+/HER2-

PDF

Read this ClinicalThought Commentary translated in Brazilian Portuguese with answers from experts to healthcare professional questions from a recent live event focused on CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer care. 

Released: August 19, 2024

Expiration: August 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation